Our Technology

Gentel's surface chemistry technology is based on a patented process that produces a highly uniform, optically clear nitrocellulose film on microscope slides. Optically clear nitrocellulose films reduce background fluorescence by more than 98% compared to traditional porous nitrocellulose slides and yield as much as five times higher signal-to-noise ratio in an immunoassay. Antibodies irreversibly bind to nitrocellulose films without modification and remain functionally active for more than six months. Antibody arrays on Gentel slides capture proteins from serum and other complex samples in a quantitative fashion to deliver robust, quantitative immunoassay data.

Gentel has combined this proprietary surface chemistry with a world-class assay development team. We recently added a fully automated, high-throughput platform for quantitation of proteins in biological samples developed and validated at GlaxoSmithKline. Scientists from GlaxoSmithKline's protein chip team joined Gentel to implement this platform.

Gentel scientists have developed and commercialized a number of quantitative multiplex immunoassays (QMI) for determining protein concentrations in serum and plasma. These immunoassays include human and mouse cytokines and proteins related to blood coagulation, metabolic disease, neurodegenerative disease and cancer. Gentel's fully automated cytokine QMI achieves industry-leading, sub-pg/mL sensitivity with coefficients of variation (CV's) of less than 10%.